Table 3.

Endometrial Cancer Characteristics

Germline Testing Group
	LS (n = 17)		MMRD+/germline−(n = 12)		MMRD+/VUS (n = 3)		sporadic MSI-H (n = 15)		Total (n = 47)		p-value
	N	%	N	%	N	%	N	%	N	%
Location											0.0407
Lower Uterine	6	35.3	3	25.0	1	33.3	0	0.0	10	21.3
Uterine Body	11	64.7	9	75.0	2	66.7	15	100.0	37	78.7
Histology											0.1112
Endometrioid	14	82.4	10	83.3	2	66.7	14	93.3	40	85.1
Serous	1	5.9	0	0.0	0	0.0	0	0.0	1	2.1
Mixed high	2	11.8	0	0.0	0	0.0	1	6.7	3	6.4
Clear cell	0	0.0	2	16.7	0	0.0	0	0.0	2	4.3
Papillary	0	0.0	0	0.0	1	33.3	0	0.0	1	2.1
Grade4											0.9867
1	3	20.0	2	18.2	0	0.0	2	13.3	7	16.3
2	9	60.0	7	63.6	2	100.0	11	73.3	29	67.4
3	3	20.0	2	18.2	0	0.0	2	13.3	7	16.3
Stage											0.2890
I	7	53.8	5	55.6	0	0.0	8	61.5	20	52.6
II	2	15.4	0	0.0	2	66.7	2	15.4	6	15.8
III	3	23.1	4	44.4	1	33.3	2	15.4	10	26.3
IV	1	7.7	0	0.0	0	0.0	1	7.7	2	5.3
IHC a (staining absent)											0.0002
MLH1&PMS2*	3	17.6	7	58.3	1	33.3	15	100.0	26	55.3
MSH2 & MSH6*	10	58.8	4	33.3	2	66.7	0	0.0	16	34.0
PMS2	1	5.9	0	0.0	0	0.0	0	0.0	1	2.1
MSH6	2	11.8	0	0.0	0	0.0	0	0.0	2	4.3
No loss staining	1	5.9	1	8.3	0	0.0	0	0.0	2	4.3
MSI											0.8603
High	9	90.0	8	88.9	3	100.0	11	91.7	31	91.2
Low	1	10.0	0	0.0	0	0.0	1	8.3	2	5.9
MSS	0	0.0	1	11.1	0	0.0	0	0.0	1	2.9

^*There were 3 individuals overall (1 LS, 1 MMRD+/germline−, 1 sporadic MSI-H) who had staining performed for MLH1 only before staining for PMS2 was available. These individuals have been added to the statistics for MLH1&PMS2, as they likely would have stained negative for PMS2 if it had been available.

Significant pairwise comparisons (alpha < 0.008):

^aLS vs. Sporadic MSI-H